OSE Immunotherapeutics Logo

OSE Immunotherapeutics

ISIN: FR0012127173 | Ticker: OSE | LEI: 969500HIUWVGY6NZSM05
Sector: Health CareSub-Industry: Biotechnology
Country: France

About OSE Immunotherapeutics

Company Description

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics has 70 employees and is listed on Euronext Paris.

Year founded

2016

Served area

Worldwide

Headcount

70

Headquarters

22 Boulevard Benoni Goullin, 44200 Nantes – France

Financial statements

Download as Excel
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Assets N/A 96,973,000.00 101,876,000.00
Noncurrent Assets N/A 57,141,000.00 57,670,000.00
Property Plant And Equipment N/A 947,000.00 926,000.00
Intangible Assets Other Than Goodwill N/A 52,600,000.00 51,122,000.00
Deferred Tax Assets N/A 165,000.00 173,000.00
Current Assets N/A 39,832,000.00 44,206,000.00
Current Trade Receivables N/A 1,074,000.00 772,000.00
Cash and cash equivalents 25,842,000.00 29,368,000.00 33,579,000.00
Shortterm Deposits Classified As Cash Equivalents N/A N/A 1,000.00
Other Current Assets N/A 9,390,000.00 9,854,000.00
Equity And Liabilities N/A 96,973,000.00 101,876,000.00
Equity 58,536,000.00 61,364,000.00 47,890,000.00
Issued Capital N/A 3,597,000.00 3,705,000.00
Share Premium N/A 65,449,000.00 65,605,000.00
Treasury Shares N/A 93,000.00 160,000.00
Noncurrent Liabilities N/A 21,481,000.00 37,224,000.00
Noncurrent Provisions N/A 531,000.00 710,000.00
Deferred Tax Liabilities N/A 2,080,000.00 1,748,000.00
Longterm Borrowings N/A 16,552,000.00 30,801,000.00
Current Liabilities N/A 14,128,000.00 16,761,000.00
Trade And Other Current Payables To Trade Suppliers N/A 10,286,000.00 9,607,000.00
Current Payables On Social Security And Taxes Other Than Income Tax N/A 2,108,000.00 3,724,000.00
Current Tax Liabilities Current N/A 2,000.00 14,000.00
Other Current Liabilities N/A 1,088,000.00 1,050,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 50,000.00 1,611,000.00
Line item in (eur) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
Revenue 10,432,000.00 26,306,000.00
Other Revenue 13,000.00 0.00
Revenue From Contracts With Customers 10,418,000.00 26,306,000.00
Expense From Sharebased Payment Transactions With Employees 2,283,000.00 3,773,000.00
Profit Loss From Operating Activities -18,989,000.00 -16,625,000.00
Finance Income 31,000.00 267,000.00
Finance Costs 288,000.00 856,000.00
Profit Loss Before Tax -19,246,000.00 -17,213,000.00
Income Tax Expense Continuing Operations -2,692,000.00 -364,000.00
Profit (loss) -16,555,000.00 -16,850,000.00
Profit Loss Attributable To Owners Of Parent -16,555,000.00 -16,850,000.00
Line item in (eur) 01.01.2020 01.01.2021 01.01.2022
Profit (loss) N/A -16,555,000.00 -16,850,000.00
Adjustments For Income Tax Expense N/A -2,692,000.00 -364,000.00
Adjustments For Increase Decrease In Trade Account Payable N/A N/A 679,000.00
Adjustments For Depreciation And Amortisation Expense N/A 273,000.00 1,970,000.00
Adjustments For Provisions N/A 0.00 289,000.00
Adjustments For Sharebased Payments N/A 1,787,000.00 2,944,000.00
Cash Flows From Used In Operations N/A -16,306,000.00 -10,612,000.00
Income Taxes Paid Refund Classified As Operating Activities N/A 50,000.00 0.00
Cash Flows From Used In Operating Activities N/A -19,550,000.00 -9,919,000.00
Cash Flows From Used In Investing Activities N/A -504,000.00 -827,000.00
Proceeds From Issuing Shares N/A 18,630,000.00 265,000.00
Proceeds From Borrowings Classified As Financing Activities N/A 6,960,000.00 15,281,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 325,000.00 40,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 482,000.00 549,000.00
Cash Flows From Used In Financing Activities N/A 23,580,000.00 14,957,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 0.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A 3,526,000.00 4,211,000.00
Cash and cash equivalents 25,842,000.00 29,368,000.00 33,579,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Date Trading entity / Person Association Trade type Volume
19.06.24 None Other Other EUR 35,700.00
17.06.24 None Other Other EUR 35,800.00
17.06.24 None Other Other EUR 35,700.00
13.06.24 None Other Sell EUR 45,879.09
03.06.24 None Other Sell EUR 314,512.00

Capital markets information

ISIN

FR0012127173

LEI

969500HIUWVGY6NZSM05

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

Euronext Paris

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.